Cargando…
Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)—PathIES
PURPOSE: The prognostic and predictive values of the MAPK/AKT/ERα phosphorylation axis (pT202/T204MAPK, pT308AKT, pS473AKT, pS118ERα and pS167ERα) in primary tumours were assessed to determine whether these markers can differentiate between patient responses for switching adjuvant endocrine therapy...
Autores principales: | Szijgyarto, Zsolt, Flach, Koen D., Opdam, Mark, Palmieri, Carlo, Linn, Sabine C., Wesseling, Jelle, Ali, Simak, Bliss, Judith M., Cheang, Maggie Chon U., Zwart, Wilbert, Coombes, R. Charles |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6491661/ https://www.ncbi.nlm.nih.gov/pubmed/30680659 http://dx.doi.org/10.1007/s10549-018-05110-x |
Ejemplares similares
-
Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES
por: Cheang, M. C. U., et al.
Publicado: (2017) -
Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)—a randomised controlled trial of exemestane versus continued tamoxifen after 2–3 years tamoxifen
por: Bertelli, G., et al.
Publicado: (2010) -
Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation
por: Fallowfield, L J, et al.
Publicado: (2012) -
Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study
por: van Nes, J. G. H., et al.
Publicado: (2012) -
Effects of tamoxifen and exemestane on cognitive function in postmenopausal patients with breast cancer
por: Lee Meeuw Kjoe, Philippe R, et al.
Publicado: (2023)